248 related articles for article (PubMed ID: 25544376)
21. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies.
Kuwano M; Uchiumi T; Hayakawa H; Ono M; Wada M; Izumi H; Kohno K
Cancer Sci; 2003 Jan; 94(1):9-14. PubMed ID: 12708467
[TBL] [Abstract][Full Text] [Related]
22. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
[TBL] [Abstract][Full Text] [Related]
23. [Molecular mechanism of the stress induction of MDR1 gene].
Kohno K
Nihon Rinsho; 1997 May; 55(5):1054-8. PubMed ID: 9155152
[TBL] [Abstract][Full Text] [Related]
24. Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
Chua PJ; Lim JP; Guo TT; Khanna P; Hu Q; Bay BH; Baeg GH
Int J Oncol; 2018 Dec; 53(6):2579-2589. PubMed ID: 30221675
[TBL] [Abstract][Full Text] [Related]
25. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R
Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417
[TBL] [Abstract][Full Text] [Related]
26. Expression of Y box-binding protein-1 correlates with DNA topoisomerase IIalpha and proliferating cell nuclear antigen expression in lung cancer.
Gu C; Oyama T; Osaki T; Kohno K; Yasumoto K
Anticancer Res; 2001; 21(4A):2357-62. PubMed ID: 11724293
[TBL] [Abstract][Full Text] [Related]
27. ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
Kato T; Fujita Y; Nakane K; Kojima T; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2012 Jan; 417(3):966-71. PubMed ID: 22206665
[TBL] [Abstract][Full Text] [Related]
28. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression.
Bargou RC; Jürchott K; Wagener C; Bergmann S; Metzner S; Bommert K; Mapara MY; Winzer KJ; Dietel M; Dörken B; Royer HD
Nat Med; 1997 Apr; 3(4):447-50. PubMed ID: 9095180
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
[TBL] [Abstract][Full Text] [Related]
30. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
31. Intracellular localization and content of YB-1 protein in multidrug resistant tumor cells.
Vaiman AV; Stromskaya TP; Rybalkina EY; Sorokin AV; Guryanov SG; Zabotina TN; Mechetner EB; Ovchinnikov LP; Stavrovskaya AA
Biochemistry (Mosc); 2006 Feb; 71(2):146-54. PubMed ID: 16489918
[TBL] [Abstract][Full Text] [Related]
32. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
33. miR-137 restoration sensitizes multidrug-resistant MCF-7/ADM cells to anticancer agents by targeting YB-1.
Zhu X; Li Y; Shen H; Li H; Long L; Hui L; Xu W
Acta Biochim Biophys Sin (Shanghai); 2013 Feb; 45(2):80-6. PubMed ID: 23178914
[TBL] [Abstract][Full Text] [Related]
34. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
35. A novel EGR-1 dependent mechanism for YB-1 modulation of paclitaxel response in a triple negative breast cancer cell line.
Lasham A; Mehta SY; Fitzgerald SJ; Woolley AG; Hearn JI; Hurley DG; Ruza I; Algie M; Shelling AN; Braithwaite AW; Print CG
Int J Cancer; 2016 Sep; 139(5):1157-70. PubMed ID: 27072400
[TBL] [Abstract][Full Text] [Related]
36. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
37. Human AP endonuclease (APE1/Ref-1) and its acetylation regulate YB-1-p300 recruitment and RNA polymerase II loading in the drug-induced activation of multidrug resistance gene MDR1.
Sengupta S; Mantha AK; Mitra S; Bhakat KK
Oncogene; 2011 Jan; 30(4):482-93. PubMed ID: 20856196
[TBL] [Abstract][Full Text] [Related]
38. ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Oprea-Lager DE; Bijnsdorp IV; VAN Moorselaar RJ; VAN DEN Eertwegh AJ; Hoekstra OS; Geldof AA
Anticancer Res; 2013 Feb; 33(2):387-91. PubMed ID: 23393328
[TBL] [Abstract][Full Text] [Related]
39. Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.
Shiota M; Izumi H; Tanimoto A; Takahashi M; Miyamoto N; Kashiwagi E; Kidani A; Hirano G; Masubuchi D; Fukunaka Y; Yasuniwa Y; Naito S; Nishizawa S; Sasaguri Y; Kohno K
Cancer Res; 2009 Apr; 69(7):3148-56. PubMed ID: 19318582
[TBL] [Abstract][Full Text] [Related]
40. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
